Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI
- 14 September 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Invasive Cardiology
- Vol. 76 (12), 1468-1483
- https://doi.org/10.1016/j.jacc.2020.06.085
Abstract
No abstract availableThis publication has 69 references indexed in Scilit:
- Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting StentsJAMA, 2013
- Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trialThe Lancet, 2013
- A New Strategy for Discontinuation of Dual Antiplatelet TherapyJournal of Invasive Cardiology, 2012
- Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting StentsJournal of the American College of Cardiology, 2012
- Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trialThe Lancet, 2011
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsJournal of the American College of Cardiology, 2011
- Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research ConsortiumEuropean Heart Journal, 2010
- Clinical End Points in Coronary Stent TrialsJournal of the American College of Cardiology, 2007
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionThe New England Journal of Medicine, 1993
- Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.Journal of the American College of Cardiology, 1987